FDA Finds No Clinical Differences in Novartis Biosimilar of Amgen Drug

Jan 06, 2015

The Wall Street Journal

The U.S. market may be close to having the first biosimilar available for patients, according to an article in the Wall Street Journal.

FDA staff said there are “no clinically meaningful differences” between Neupogen, an Amgen medicine that is used to prevent infections during chemotherapy, and a biosimilar version from Sandoz. If approved, the Sandoz version would become the first biosimilar in the United States, by way of a regulatory pathway that was created for these medicines three years ago, the article said. The Sandoz drug is already being sold in more than 40 countries outside of the U.S. under the brand name Zarzio. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments